Zhejiang Jolly Pharmaceutical Co Ltd (SHE:300181) — Market Cap & Net Worth
Market Cap & Net Worth: Zhejiang Jolly Pharmaceutical Co Ltd (300181)
Zhejiang Jolly Pharmaceutical Co Ltd (SHE:300181) has a market capitalization of $1.56 Billion (CN¥10.67 Billion) as of May 4, 2026. Listed on the SHE stock exchange, this China-based company holds position #7228 globally and #1710 in its home market, demonstrating a -4.46% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Zhejiang Jolly Pharmaceutical Co Ltd's stock price CN¥15.21 by its total outstanding shares 701387335 (701.39 Million). Analyse 300181 operating cash flow to see how efficiently the company converts income to cash.
Zhejiang Jolly Pharmaceutical Co Ltd Market Cap History: 2015 to 2026
Zhejiang Jolly Pharmaceutical Co Ltd's market capitalization history from 2015 to 2026. Data shows growth from $1.08 Billion to $1.56 Billion (5.47% CAGR).
Zhejiang Jolly Pharmaceutical Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Zhejiang Jolly Pharmaceutical Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.61x
Zhejiang Jolly Pharmaceutical Co Ltd's market cap is 0.61 times its annual revenue
Latest Price to Earnings (P/E) Ratio
3.10x
Zhejiang Jolly Pharmaceutical Co Ltd's market cap is 3.10 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $1.08 Billion | $670.86 Million | $84.77 Million | 1.61x | 12.77x |
| 2016 | $837.91 Million | $840.04 Million | $72.02 Million | 1.00x | 11.63x |
| 2017 | $705.02 Million | $679.04 Million | $45.14 Million | 1.04x | 15.62x |
| 2018 | $477.21 Million | $730.26 Million | $20.75 Million | 0.65x | 23.00x |
| 2019 | $472.37 Million | $911.16 Million | $25.59 Million | 0.52x | 18.46x |
| 2020 | $553.77 Million | $1.09 Billion | $88.80 Million | 0.51x | 6.24x |
| 2021 | $1.11 Billion | $1.46 Billion | $179.41 Million | 0.76x | 6.18x |
| 2022 | $1.04 Billion | $1.81 Billion | $273.01 Million | 0.58x | 3.81x |
| 2023 | $1.06 Billion | $1.94 Billion | $382.94 Million | 0.55x | 2.78x |
| 2024 | $1.58 Billion | $2.58 Billion | $507.77 Million | 0.61x | 3.10x |
Competitor Companies of 300181 by Market Capitalization
Companies near Zhejiang Jolly Pharmaceutical Co Ltd in the global market cap rankings as of May 4, 2026.
Key companies related to Zhejiang Jolly Pharmaceutical Co Ltd by market ranking:
- Eli Lilly and Company (NYSE:LLY): Ranked #16 globally with a market cap of $862.20 Billion USD.
- Eli Lilly and Company (SA:LILY34): Ranked #17 globally with a market cap of $853.51 Billion USD ( R$4.35 Trillion BRL).
- Johnson & Johnson (NYSE:JNJ): Ranked #23 globally with a market cap of $547.37 Billion USD.
- AbbVie Inc (NYSE:ABBV): Ranked #37 globally with a market cap of $365.30 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #16 | Eli Lilly and Company | NYSE:LLY | $862.20 Billion | $963.33 |
| #17 | Eli Lilly and Company | SA:LILY34 | $853.51 Billion | R$153.70 |
| #23 | Johnson & Johnson | NYSE:JNJ | $547.37 Billion | $227.19 |
| #37 | AbbVie Inc | NYSE:ABBV | $365.30 Billion | $206.60 |
Zhejiang Jolly Pharmaceutical Co Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, Zhejiang Jolly Pharmaceutical Co Ltd's market cap moved from $1.08 Billion to $ 1.56 Billion, with a yearly change of 5.47%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥1.56 Billion | -5.88% |
| 2025 | CN¥1.66 Billion | +5.21% |
| 2024 | CN¥1.58 Billion | +48.33% |
| 2023 | CN¥1.06 Billion | +2.20% |
| 2022 | CN¥1.04 Billion | -6.20% |
| 2021 | CN¥1.11 Billion | +100.19% |
| 2020 | CN¥553.77 Million | +17.23% |
| 2019 | CN¥472.37 Million | -1.02% |
| 2018 | CN¥477.21 Million | -32.31% |
| 2017 | CN¥705.02 Million | -15.86% |
| 2016 | CN¥837.91 Million | -22.61% |
| 2015 | CN¥1.08 Billion | -- |
End of Day Market Cap According to Different Sources
On May 4th, 2026 the market cap of Zhejiang Jolly Pharmaceutical Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.56 Billion USD |
| MoneyControl | $1.56 Billion USD |
| MarketWatch | $1.56 Billion USD |
| marketcap.company | $1.56 Billion USD |
| Reuters | $1.56 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Zhejiang Jolly Pharmaceutical Co Ltd
Zhejiang Jolly Pharmaceutical Co.,LTD engages in the research, production, and marketing of Chinese medicinal products in the People's Republic of China and internationally. It offers Wuling capsule to treat insomnia, amnesia, heart palpitations, lack of energy, lassitude in loin and legs, and giddy tinnitus, as well as deficiency of energy and weak pulse caused by the disharmony of heart and kid… Read more